Incannex Healthcare Inc. (IXHL): Shareholders' Equity
$67.37M
As of 2026-06-30
$66.14M
As of 2026-09-30
+47.9%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $67.37M | +403.2% | 2026-09-25, Balance as of period end |
| 2025-06-30 | $13.39M | +19.4% | 2026-09-25, Balance as of period end |
| 2024-06-30 | $11.22M | -46.1% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $20.82M | n/a | 2024-09-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $67.37M | +403.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare IXHL, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗